EDIT News and Press, Editas Medicine Inc.

2024-06-25 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, ...

All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...

2024-06-11 04:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-30 09:49:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the past 12 months or so, a surge of bullish sentiment has overtaken Wall Street, with investors backing AI-powered growth stocks . In this excitement, a handful of stocks have dominated...

2024-05-15 20:25:24 ET Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 14:05 ET Company Participants Gilmore O’Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets ...

2024-05-15 08:58:29 ET Summary Editas Medicine shares have underperformed the S&P 500 by over 108% in the last three years. The company has a promising pipeline and is making strides in preclinical and clinical trials. However, weak financials and the risk associated with ...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizga...

Research includes the first-ever application of AsCas12a in vivo , optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWI...

2024-05-09 13:12:00 ET Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday. While one analyst trimmed her price target on the stock in response, she's still extremely bullish on its prospects. In fact, s...